Q4 2024 Oncology Institute Inc Earnings Call Transcript
Key Points
- Revenue increased by 21% over the previous year, driven by growth in value-based patient services and pharmacy operations.
- The company signed six new contracts covering over 270,000 lives, expanding its reach and proving its model outside of California.
- Pharmacy and medically integrated dispensaries grew rapidly, with a 73% annualized growth in 2024.
- The company achieved a sequential improvement in adjusted EBITDA in the second half of the year through capitated contract growth and drug margin improvement.
- TOI successfully restructured its facility agreement, reducing outstanding debt and eliminating certain financial covenants, enhancing financial flexibility.
- Overall financial performance in 2024 did not meet expectations, with a net loss of $64.6 million for the year.
- Adjusted EBITDA for Q4 2024 was negative $7.8 million, worse than the negative $6.3 million in Q4 2023.
- Gross profit for 2024 decreased by 9.4% compared to 2023, largely due to lower infusion drug margins and higher clinical payroll costs.
- The company experienced a $3 million onetime reduction in fee-for-service revenue unrelated to Q4 dates of service.
- Despite improvements, the company still anticipates negative adjusted EBITDA for 2025, with expected losses in the first half of the year.
Good afternoon, and welcome to The Oncology Institute's fourth-quarter and full year 2024 earnings conference call. Today's call is being recorded, and we have allocated one hour for prepared remarks and questions and answers.
At this time, I'd like to turn the conference over to Mark Hueppelsheuser, General Counselor at TOI. Thank you. You may begin.
The press release announcing The Oncology Institute's results for the fourth quarter and full year 2024 are available at the Investors section of the company's website, theoncologyinstitute.com. A replay of this call will also be available at the company's website after the conclusion of this call.
Before we get started, I would like to remind you of the company's safe harbor language included within the company's press release for the fourth quarter and full year 2024. Management may make forward-looking statements, including guidance and underlying assumptions. Forward-looking statements are based on expectations that involve risks
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
